Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP-671 in Chronic Kidney Disease and Hyperuricaemia
NCT07323095Phase 2Recruiting
- Sponsor
- Atom Therapeutics
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of lingdolinurad in chronic kidney disease (CKD), hyperuricemia, sponsored by Atom Therapeutics. Started Oct 2026; status: recruiting.
02
Drugs
lingdolinurad
03
Conditions
chronic kidney disease (CKD)hyperuricemia
Beyond the preview
Go deeper on NCT07323095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07323095.